Skip to main content
Premium Trial:

Request an Annual Quote

Integrated DNA Technologies, 3CR Bioscience to Offer Custom Genotyping Screening Assays

NEW YORK – Integrated DNA Technologies (IDT) said today that it has partnered with UK firm 3CR Bioscience to offer customized assays for genotypic screening applications, which the firms believe will speed up and curb costs of high-volume genotyping.

As part of the collaboration, the team is integrating IDT's oligo synthesis technology with 3CR's PCR Allele Competitive Extension (PACE) Genotyping Master Mix and expertise in designing allele-specific assays. 

According to IDT, a unit of Danaher, researchers will be able to work with an integrated technical service team to design and order custom PACE SNP assays. The firms believe the new service will lower the cost per sample compared to existing assays on the market. 

"Our joint efforts provide a system that combines the superior performance of the 3CR master mix with high-quality oligonucleotides from IDT," Ben Viering, IDT VP of business development, said in a statement. "The combination provides a genotyping solution that is robust, highly sensitive, and economical." 

Financial details of the agreement were not disclosed. 

The firms expect agricultural biologists to benefit from the collaboration, as it sees the new service ideal for high-volume genotyping screening required for plant breeding experiments. 

"Our high-performance PACE master mix, based on a proprietary polymerase technology, pairs well with IDT's industry-leading quality oligo synthesis to provide a reliable genotyping solution," Steve Asquith, 3CR's managing director, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.